drugset / Trial / NCT00609817
Safety and Efficacy Study of GCS-100LE in the Treatment of Multiple Myeloma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
A Phase 1, open-label, dose escalation, multi-center study in patients who have been diagnosed with multiple myeloma and who have relapsed or have refractory/relapsed disease after treatment with at least 2 prior therapies.
Timeline
- Start
- 2008-05
- Primary completion
- 2009-04
- Completion
- 2009-04
Outcome
Outcome not reported
Stopped (Business): “Lack of funding”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1.3 mg/m2 | — |
| Subject | Dexamethasone | Small molecule | 20 mg | — |
| Subject | GCS-100 | Unknown | 160 mg/m2 | Intravenous |
| Subject | GCS-100 | Unknown | 210 mg/m2 | Intravenous |
| Subject | GCS-100 | Unknown | 280 mg/m2 | Intravenous |
| Subject | GCS-100 | Unknown | 370 mg/m2 | Intravenous |